Opinion|Videos|June 12, 2024
Cost, Value, and Affordability of Treatment for Alzheimer Disease
A comprehensive discussion on the value of therapies for Alzheimer disease based on cost vs outcome, and unmet needs in the overall treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Could you describe drug cost versus value versus affordability?
Advertisement
Related to this article
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Acoramidis Linked to Fewer Hospitalizations Than Tafamidis in ATTR-CM
3
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
4
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
5